COIOSDeep risk insights through multi-disciplinary research across the globe
Item confirms Peer-reviewed Added

Denosumab discontinuation in Japan is rarely followed by sequential osteoporosis therapy

Of 37,526 Japanese adults who stopped denosumab, 16.3% began sequential osteoporosis therapy within one year.

This descriptive study used a Japanese claims database covering April 2014 to March 2024. It included 37,526 adults aged 40 or over who started denosumab and stopped after at least two doses. Stopping meant a gap of more than 240 days after the last dose. Within a year, 29.6% resumed denosumab after that gap, 50.9% had no further treatment and 16.3% began sequential therapy. Oral bisphosphonates (26.7%) and romosozumab (22.2%) were the commonest sequential therapies. The study did not compare fracture risk between treatment patterns, though 5.4% had a fragility fracture within a year.

Why it is interesting: Half of patients who stopped denosumab had no further osteoporosis treatment within a year. Timing differed by drug, with romosozumab most often started 180-209 days after stopping.

Source
Archives of Osteoporosis, 12 November 2026
Paper
Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study
Authors
Yoshiyama T, Fukasawa T, Masuda S, Matsuda S, Kawakami K
DOI
10.1007/s11657-026-01812-8
Type
Peer-reviewed article
Design
Descriptive cohort in a Japanese claims database, 37,526 adults aged 40+ newly initiating denosumab and discontinuing after ≥2 doses, April 2014-March 2024, 1-year follow-up
Verdict
Confirms prior evidence
Driver
Adherence and persistence

Other drivers in Behavioural science